FORM
6-K
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Report
of Foreign Issuer
Pursuant
to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
For the
month of September 2008
Commission
File Number: 001-15152
SYNGENTA
AG
(Translation
of registrant’s name into English)
Schwarzwaldallee
215
4058
Basel
Switzerland
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F:
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1):
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7):
Indicate
by check mark whether by furnishing the information contained in this Form, the
Registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934:
If “Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): N/A
Re: SYNGENTA
AG
Press
Release: "Board appoints new
Head of Global R&D to Executive Committee, proposes retiring Head to join
Board of Directors"
Filed
herewith is a press release related to Syngenta AG. The full text of the press
release follows:
# #
#
Syngenta International AG
Media
Office
CH-4002 Basel
Switzerland
Tel:
+41 61 323 23 23
Fax:
+41 61 323 24 24
www.syngenta.com
|
Médard
Schoenmaeckers
Switzerland
+41 61 323 2323
Anne
Burt
USA
+1 202 628 2372
|
Jennifer
Gough
Switzerland
+41 61 323 5059
USA
+1 202 737 6521
John
Hudson
Switzerland +41
61 323 6793
USA
+1 202 737 6520
|
Board
appoints new Head of Global R&D to Executive Committee, proposes retiring
Head to join Board of Directors
Syngenta
announced today that Dr David Lawrence, Head of Global Research and Development,
will be retiring from Syngenta in April 2009. He will step down from the
Executive Committee on 1 October 2008. From the same date, Dr Alejandro Aruffo
(49) is appointed to the Executive Committee to succeed Lawrence. Until April,
Aruffo and Lawrence will work closely together to ensure a seamless
transition.
At the
Syngenta Annual General Meeting in April 2009, Dr Peter Doyle, a founding member
of the Board of Directors and Chairman of the Science and Technology Advisory
Board, will retire having reached the statutory age limit of 70. Also at the
2009 Annual General Meeting, the Board of Directors will propose to shareholders
that David Lawrence be appointed to the Board to fill the vacancy created by
Peter's retirement. This will enable Syngenta to continue to benefit from David
Lawrence’s extensive experience.
Michael
Mack, Chief Executive Officer said: “I would like to express my warmest
appreciation to Dave for the 35 years he has served Syngenta and its legacy
organizations. Dave worked across the full spectrum of the R&D function
before joining the Syngenta Executive Committee in 2002. In this capacity, he
has played a pivotal role in the success of Syngenta through his leadership of
the R&D organization”.
Alejandro
Aruffo joined Syngenta earlier this year from Abbott Laboratories where he most
recently served as Vice President, Global Pharmaceutical Development. Prior to
this position he served as Vice President, Abbott Immunology R&D and
President of the Abbott Bioresearch Center. He also served in a number of
positions at Bristol-Myers Squibb. Alejandro Aruffo received bachelor's degrees
in Chemistry and Mathematics from the University of Washington and a doctorate
in Biophysics from Harvard University.
Syngenta
is a world-leading agribusiness committed to sustainable agriculture through
innovative research and technology. The company is a leader in crop protection,
and ranks third in the high-value commercial seeds market. Sales in 2007 were
approximately $9.2 billion. Syngenta employs over 21,000 people in more than
90 countries. Syngenta is listed on the Swiss stock exchange (SYNN) and in
New York (SYT). Further information is available at www.syngenta.com.
Syngenta
Cautionary Statement Regarding Forward-Looking Statements
This
document contains forward-looking statements, which can be identified by
terminology such as ‘expect’, ‘would’, ‘will’, ‘potential’, ‘plans’,
‘prospects’, ‘estimated’, ‘aiming’, ‘on track’ and similar expressions. Such
statements may be subject to risks and uncertainties that could cause the actual
results to differ materially from these statements. We refer you to Syngenta's
publicly available filings with the U.S. Securities and Exchange Commission for
information about these and other risks and uncertainties. Syngenta assumes no
obligation to update forward-looking statements to reflect actual results,
changed assumptions or other factors. This document does not constitute, or form
part of, any offer or invitation to sell or issue, or any solicitation of any
offer, to purchase or subscribe for any ordinary shares in Syngenta AG, or
Syngenta ADSs, nor shall it form the basis of, or be relied on in connection
with, any contract therefor.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
|
SYNGENTA AG
|
|
|
|
|
|
|
|
|
|
Date:
|
September
12, 2008
|
|
By:
|
/s/
Christoph Mäder
|
|
|
|
|
|
Name:
|
Christoph
Mäder
|
|
|
|
|
|
Title:
|
Head
Legal and Taxes
|
|